Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board
December 20, 2022 07:30 ET
|
Paratek Pharmaceuticals
BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Company’s independent directors of the Board have appointed Jeffrey Stein, PhD as its...
Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield
December 19, 2022 07:30 ET
|
Paratek Pharmaceuticals
100% Survival Rate in Anthrax-infected Rabbits Treated with OmadacyclineTotal Revenue Recognition to Paratek of $38.1 Million BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals,...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 01, 2022 17:45 ET
|
Paratek Pharmaceuticals
BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 21, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million
November 03, 2022 16:05 ET
|
Paratek Pharmaceuticals
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.5 Million from the Core Commercial Business, a 31% increase from $19.4 Million in Third Quarter 2021 -- Initiated Rabbit Pilot Efficacy Study...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
November 01, 2022 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference
November 01, 2022 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract
October 31, 2022 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces the commercial availability of U.S.-produced NUZYRA® (omadacycline) tablets. This milestone...
Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3
October 25, 2022 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Thursday, Nov. 3 at 4:30...
Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022
October 13, 2022 16:05 ET
|
Paratek Pharmaceuticals
Highlights include data from non-clinical and microbiology programs and real-world patient use BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a...